A New Regime Takes The Reins At Teva

New CEO Kare Schultz has established a new leadership team and structure at the generic drug giant, as head of R&D Michael Hayden, Global Specialty Medicines CEO Rob Koremans and Global Generics Medicines CEO Dipankar Bhattacharjee will all leave at the end of the year.

sales manager giving advice to his couple clients

It's time for a fresh leadership team to try turning around the troubled generic drug giant Teva Pharmaceutical Industries Ltd. now that the new CEO Kare Schultz has made his first big move, but the task won't be easy.

Teva announced a new organizational structure and corporate leadership team Nov. 27 that will almost entirely change the big pharma's...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Leadership

More from Generics Bulletin